Policy

Policy articles analyzing social and public policy including impacts on economics, open dialog, and social life. Articles on the topic of policy at Brownstone Institute are translated into multiple languages.

Filter posts by category

Florida Surgeon General Highlights Vaccine Injuries, Calls on NIH to Act

Florida Surgeon General Highlights Vaccine Injuries, Calls on NIH to Act

SHARE | PRINT | EMAIL

At a press conference, Florida Surgeon General Dr Joseph Ladapo made an urgent call for the NIH program funding to help Americans injured by Covid-19 vaccines and expressed support for the federal changes in the HHS’s restrictive Covid-19 vaccine recommendations.

Florida Surgeon General Highlights Vaccine Injuries, Calls on NIH to Act Read Journal Article

NIH Director Details Crackdown on Fees Monopoly Publishers Charge

NIH Director Details Crackdown on Fees Monopoly Publishers Charge

SHARE | PRINT | EMAIL

In an exclusive interview with The DisInformation Chronicle, National Institutes of Health Director Jay Bhattacharya explains his latest policy to control monopoly science publishers now raking in hundreds of millions of dollars from taxpayers.

NIH Director Details Crackdown on Fees Monopoly Publishers Charge Read Journal Article

REPPARE University of Leeds - Brownstone Institute

Rethinking US Global Health Funding: Welcome, and Long Overdue

SHARE | PRINT | EMAIL

We agree that the international community should continue to support less-resourced members. However, we disagree that this should consist of perpetual and increasing payments to centralized agencies such as GFATM, GAVI, and the Pandemic Fund, or donor bureaucracies like USAID.

Rethinking US Global Health Funding: Welcome, and Long Overdue Read Journal Article

Retsef Levi Explains His Vote against Routine RSV Monoclonal Use in Newborns

Retsef Levi Explains His Vote against Routine RSV Monoclonal Use in Newborns

SHARE | PRINT | EMAIL

Levi is no stranger to weighing risk. A professor at MIT with deep experience in data analytics and risk-based decision-making, he had combed through five clinical trials of RSV monoclonals, including clesrovimab and its predecessor, nirsevimab.

Retsef Levi Explains His Vote against Routine RSV Monoclonal Use in Newborns Read Journal Article